Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The 'nightmare' regulators face when edible pot becomes legal
https://www.bnn.ca/1.1118839.1533490829
Thumbs up! !
YESSSSS!!!!
FANTASTIC!!!
Significant Updates on the horizon.
Tick tick, let’s rock!
Sure is...
Blazing a trail: as legal cannabis goes global, will Britain be next? | Society | The Guardian
https://www.theguardian.com/society/2018/jul/23/cannabis-legalization-global-wave-britain-marijuana
https://www.washingtonpost.com/news/monkey-cage/wp/2018/07/23/has-the-u-s-reached-a-tipping-point-in-marijuana-legalization/?noredirect=on&utm_term=.f080c55bdde5
Has the U.S. reached a ‘tipping point’ in marijuana legalization?
by Daniel J. Mallinson and A. Lee HannahJuly 23 at 6:00 AM
A booth advertising a delivery service for cannabis at the 420 Games in Santa Monica, Calif. (AP Photo/Richard Vogel)
Has the U.S. reached the “tipping point” in marijuana legalization? That’s what one CNN commentator said happened last month when, on June 26, Oklahoma adopted medical marijuana through a ballot initiative — making it the 30th state to do so, as you can see in the figure below.
It’s true that a lot was unusual about the Oklahoma initiative. The state approved medical marijuana with roughly 57 percent of the vote — despite the fact that the ballot measure was held in a conservative state, during a primary — when only the most committed party members tend to vote — rather than during a general election, is more permissive than many comparable laws, and was opposed by statewide Republican leaders.
So was Oklahoma’s new law indeed a tipping point? Research on policy diffusion suggests that as neighboring states, provinces, or countries adopt a policy, the pressure for adoption increases among lagging jurisdictions. And in addition to the many states, the nation’s northern neighbor Canada legalized recreational use nationwide on June 19.
The answer may lie in the pathway ahead for further expansion of marijuana liberalization. Let’s examine how that might go.
Map of states with comprehensive medical marijuana laws, as defined by the National Conference of State Legislatures.
States without a ballot initiative option might not decriminalize as easily
Notably, Oklahoma’s voters approved medical marijuana directly, rather than through the legislature. In our previous research, we found that five states legalizing medical marijuana via ballot initiatives between 1996 and 1999 helped legitimize the effort — and, beginning in 2000, a handful of legislatures followed suit.
Direct democracy is one important way that advocates successfully force the issue in some states — either through successful initiatives, as in Oklahoma, or through the threat of an initiative campaign, as in Ohio, where the legislature quickly passed a medical marijuana law to head off a 2016 initiative sponsored by Marijuana Policy Project.
As a result, as fewer and fewer of the remaining 20 states without any legal marijuana use have mechanisms for such direct referendums, it becomes less and less likely that those states will liberalize cannabis policy. In that sense, perhaps Oklahoma is not a tipping point.
[How will you know if there’s E. coli in your marijuana? No one’s figured out how to test and regulate it yet.]
The federal government’s position may shift as public opinion shifts
Somewhat like the rapid shift in public opinion toward same-sex marriage, opinions about marijuana have been changing rapidly. Overall support has swung from 25 percent in 1996 to 64 percent in 2018. Also, 2018 marked the first time that Gallup found a slim majority of Republicans (51 percent) supporting marijuana legalization. As a result, members of Congress have introduced several proposals to liberalize marijuana policy and passed a limit on the Department of Justice’s discretion in enforcing federal marijuana laws.
The limitation was prompted when, in January 2018, Attorney General Jeff Sessions instructed all U.S. attorneys to enforce the federal prohibition on marijuana possession and use. His memo may have backfired. As a result, Sens. Elizabeth Warren (D-Mass.) and Cory Gardner (R-Colo.) introduced a bill — which President Trump has said he’s likely to support — that would give state marijuana laws priority over federal marijuana prohibitions. And since Warren and Gardner have titled the bill “Strengthening the Tenth Amendment Through Entrusting States” or the STATES Act, congressional Republicans may find that they can use states’ rights arguments to maintain their conservative credentials while supporting marijuana liberalization.
[Is marijuana decriminalization possible in the Middle East?]
So far, medical and recreational marijuana have progressed through state popular initiatives and legislation. But Congress could sponsor incremental changes or even take marijuana off the schedule of nationally controlled substances — encouraging the lagging states to follow along.
The shifting narrative on medical marijuana
Direct democracy has furthered marijuana liberalization, assisted by changes in how advocates frame the issue.
Journalists and advocates have been drawing attention to recent research that shows the potential of medical cannabis to treat conditions like PTSD, epilepsy and opioid addiction. This type of coverage serves to lift the stigma on marijuana use by presenting conditions and patients that are more relatable and sympathetic than treatment for other conditions, or than recreational use.
One of us, Lee Hannah, recently conducted a content analysis of news articles about medical marijuana stories by The Washington Post from 1995 (a year prior to California adopting the first program) to 2017 to determine whether this narrative shift was being seen in news coverage. Hannah searched the newspaper archives and counted how many articles about medical marijuana were paired with specific medical conditions.
In the period from 1995 to 1999, The Washington Post ran 56 articles about medical marijuana that associated it with cancer, 73 articles that mentioned HIV/AIDS and only 7 articles associating medical marijuana with opioid addiction, epilepsy or PTSD. That relative emphasis has flipped in the last five years. The Post continued to make the connection to cancer, in 71 articles, but only 31 articles included HIV/AIDS. Meanwhile, The Post ran 195 articles that connected medical cannabis to opioid addiction (71), epilepsy (83) or PTSD (41). The results were similar when analyzing coverage in the New York Times.
Some observers argue that evidence so far suggests other policy approaches are more successful than medical marijuana in treating opioid addiction. But if interest groups can successfully persuade citizens that medical cannabis could help diminish the opioid crisis, conservative voters and state legislatures may be persuaded to make it available.
This association is not lost on lawmakers either. When former Republican Speaker of the House John A. Boehner announced his joining the board of Acreage Holdings, a cannabis corporation, he said “I’m convinced de-scheduling [removing the federal prohibition] the drug is needed so we can do research, help our veterans, and reverse the opioid epidemic ravaging our communities.” Note the emphasis on veterans and opioids.
What to expect
Whether Oklahoma’s new law is indeed a tipping point, changing public opinion and industry pressures seem to be pushing the federal government and the remaining states to make marijuana available for medical use — and probably, from there, recreational use as well.
Daniel J. Mallinson (@djmallinson) is an assistant professor of public policy and administration at Penn State Harrisburg’s School of Public Affairs.
A. Lee Hannah (@LeeHannahWSU) is an assistant professor of political science in Wright State University’s School of Public and International Affairs.
https://www.theguardian.com/world/2018/jul/22/it-hits-you-very-quickly-canada-brews-first-cannabis-beer
'It hits you very quickly': Canada brews first cannabis beer
Entrepreneurs across the country are racing to capitalise on drug’s legalisation
Ashifa KassamLast modified on Mon 23 Jul 2018 01.50 BST
Scientists in a small Ontario laboratory are testing enzymes and experimenting with fermentation. Their techniques are not new, but their focus is a first. They are developing what is being described as the world’s first beer brewed from cannabis.
Most cannabis beers on the market are brewed from barley and infused with marijuana oil, according to Dooma Wendschuh of Province Brands, the Toronto startup behind the product. “That’s not what we do. Our beer is brewed from the stalks, stem and roots of the cannabis plant.”
It is a story playing out across Canada as entrepreneurs race to secure a foothold in what is expected to be a multibillion-dollar market. The country will become the second in the world to legalise marijuana for recreational use on 17 October.
Edibles are expected to become legal a year later, paving the way for cannabis-infused products ranging from brownies to honey. At Canopy Growth, North America’s first publicly traded cannabis company, researchers are developing a line of cannabis-infused cocktails.
Pointing to Colorado, where the legalisation of marijuana has led to a boom in edibles, analysts estimate that marijuana-related products and services could eventually be worth between C$12bn and C$22bn (£7bn and £13bn) in Canada.
Wendschuh, who is from Miami, moved to Toronto in 2016 to capitalise on Canada’s pending plans for legalisation and to create an alternative to alcohol.
“The idea came from thinking, can we create something that can serve the role that alcohol serves in our society, and can we do that using this monumental sea change that is happening in our world right now?
“I don’t think there was anywhere else in the world where we could do this business. Canada is already leading the world in creating an industry around medical cannabis and we expect them to continue to lead the world in trading and industry around adult-use cannabis.”
There were initial doubts that cannabis could be brewed into beer. “The things that we would come up with just tasted horrible,” Wendschuh said. “They tasted like rotten broccoli.”
With the help of a chemist, he eventually hit on the right combination of hops, water, yeast – and cannabis. Any alcohol produced during the processed is removed, resulting in a non-alcoholic, gluten-free beer that offers a high.
“The flavour is dry, savoury, less sweet than a typical beer flavour,” he said. “The beer hits you very quickly, which is not common for a marijuana edible.”
The aim is to create a product that, when consumed, will be roughly equivalent to a single dose of alcohol. So far the company’s experimental products have averaged about 6.5mg THC a beer.
The recipe is the backbone of the company’s plans to build a a C$50m facility that Wendschuh hopes will be the world’s first cannabis brewery. The company plans to roll out a variety of beers using different flavours and strains of cannabis, mimicking breweries that produce lagers, stouts and ales.
As the beer is brewed from the stocks, stem and roots of the cannabis plant, it offers an alternate use for what is essentially a waste product for the industry. “We take them off the grower’s hands, saving them the cost of hiring a licensed disposal company to dispose of them,” said Wendschuh.
He believes his product will be safer and healthier than alcohol, but acknowledges that it comes with its own risks. “Marijuana is not good for you and our beers are not good for you,” he said. “You should not drink them five times a day, you should not drink them first thing when you wake up in the morning. We’re not saying that.”
Instead, he described his beer as a first step in upending an industry that has become ubiquitous. “If I could create an alternative to alcohol, that’s something that would change the world,” he said. “That’s something I’m very passionate about.”
Wow!!! I’ll go take a look!
How do you attach a picture?
I have a picture of a tweed poster in a local Edmonton pub if interested in seeing.
Very nice. Thanks for posting.
Oh I forgot, hindsight is always perfect...lol
Agreed....you can always try for the very bottom but no doubt we are going back up in a big way...
More to come. Excellent!
Seen a tweed poster in a pub in Edmonton.
Looking like a solid start to the morning!
Agree. Making a mountain out of a mole hill personal reasons IMO. We have seen this before.
Thanks. Go time.
Breaking into the 40’s.
I emailed them and confirmed that it is only for media to attend:
The call that is being hosted today is not for analysts and investors. The call is for media to more efficiently handle questions for news that is expected to generate significant interest.
If you have any questions, you are welcome to email invest@canopygrowth.com.
Confirming that only media can login for the call.
Just requested the teleconference specifics. I assume others are joining as well.
Can we all say the word “GAPPER”.
Wowzers! What a NEWS day! More to come!
HUUUUUGEEEEE!
Lol. No worries here. Canopy is the real deal. Life changer for long investors!!!!!!!
SHARES IN CANOPY GROWTH MAY GROW SOME MORE ON NEW SUPPLY DEAL; FILES EARLY WARNING REPORT WITH CANOPY RIVERS INN CONNECTION WITH CLOSING OF LIVEWELL QUALIFYING TRANSACTION
LESS THAN 1 MINUTE AGO BY
Article 1Article 2Article 3Article 4Article 5Article 6Article 7Article 8Article 9Article 10
08:19 AM EDT, 06/29/2018 (MT Newswires) -- Dual listed Canopy Growth (WEED.TO, CGC) -- a diversified cannabis and hemp company -- may add to the 9.7% gained Thursday (to $40.51 apiece, nearer a 52-week high $48.72), after completing a supply agreement with the Manitoba Liquor and Lotteries Corporation. The deal involves up to 6,500 kilograms of cannabis products over the next 12 months "to meet demand from the adult use recreational cannabis market set to open on October 17, 2018," said the company.
Moreover, on late Thursday, Canopy Growth, together with Canopy Rivers, filed an early warning report under National Instrument 62-103 in relation to the closing of the previously announced qualifying transaction of LiveWell Canada Inc. In a statement the company said that in exchange for their common shares of LiveWell Foods Canada, the acquirors received an aggregate of 17.6 million common shares of Livewell, representing approximately 14.0% of the issued and outstanding common shares on a non-diluted basis.
According to a statement, Canopy Growth holds 11.7 million common shares and Canopy Rivers has 5.9 million common shares. The Acquirors had not held any common shares or convertible securities of LiveWell before the transaction.
Price: 40.51, Change: +3.58, Percent Change: +9.69
Great news!
Do shorts have to cover if there is a stock split?
Fundamentals have not changed and only got better. People will be buying big on any dips.
Despite these people saying the sky is falling, buyers are coming in based on growth which is set to sky rocket On rec marijuana legal day.
Pot companies on hiring spree ahead of lucrative legal market | CBC News
https://www.cbc.ca/news/business/pot-cannabis-marijuana-jobs-canopy-growth-medreleaf-1.4718771
That’s 3 announcements today.
Major Operational Milestones for Spectrum Cannabis in Europe: Plants and Product on the Move
Source: PR Newswire (Canada)
FRANKFURT, ODENSE, Denmark, PRAGUE and MADRID, June 25, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to provide an update on the operations of its European subsidiaries as the company continues its pursuit of sustainable market expansion, ranging from production and processing to distribution in federally legal European markets.
Major Operational Milestones for Spectrum Cannabis in Europe: Plants and Product on the Move (CNW Group/Canopy Growth Corporation)
Successful clone transfer brings Spectrum Cannabis Denmark significantly closer to producing European-grown cannabis
With the successful transfer of live cannabis clones from Madrid-based partner, Alcaliber SA ("Alcaliber") to Spectrum Cannabis Denmark ApS ("Spectrum Cannabis Denmark"), the Company continues its expansion in Europe. Soon, export from Canada to Europe will be replaced with European GMP production. With legal frameworks in place in the major economies of Germany and Italy, the Company is applying its proven strategy of investing early in best-in-class GMP production platforms to offer patients and regulators a reliable source of medical cannabis close to home.
Having sustainable regional production capacity sufficient to meet demand is core to the European strategy for Spectrum Cannabis and growing operations have now begun at the Company's greenhouse facility in Odense, Denmark.
First European Transfer Completed from Germany to the Czech Republic
Representing a significant step forward for European distribution capabilities, the Company has completed a transfer of high quality medical cannabis from Spektrum Cannabis Germany to Annabis Medical s.r.o., both wholly-owned subsidiaries of the Company.
In addition, as part of growing a consistent operation across Europe, the recently acquired Annabis Medical will be operating as Spectrum Cannabis Czech s.r.o. ("Spectrum Cannabis Czech").
Finalizing the product transfer only two months after acquiring Annabis speaks to the Company's desire to quickly serve new markets such as the Czech Republic, and cement its position in the minds of physicians and pharmacists as the preeminent cannabis producer operating within the European continent.
Comment on operations and strategic growth across Europe
"We have been and continue to be focused on being the medical cannabis leader in Europe, by bringing the expertise and credibility we have established in Canada to European markets," said Mark Zekulin, President, Canopy Growth. "These achievements involving four countries that are not Canada reflect our commitment to establishing a strong foundation in Europe, focused not only on high quality production but also medical education and a grounded dialogue about cannabis.''
In addition to its European operations, Spectrum Cannabis' established presence in Australia, South Africa, South America, and of course Canada, represent the world's largest and most diversified cannabis business.
Spectrum Cannabis - Medical Cannabis. Simplified. (Even if the operations are complex.)
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in nine countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis. Through its partly owned subsidiary, Canopy Health Innovations, Canopy Growth has invested millions of dollars toward cutting edge, commercializable research and IP development. Through its partly owned subsidiary Canopy Rivers Corporation, the Company provides resources and investment to new market entrants in order to build a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com
About Spectrum Cannabis
Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth, is dedicated to simplifying medical cannabis for patients and healthcare practitioners. Spectrum Cannabis is an international medical business which interfaces with healthcare professionals and patients around the world. Founded in Canada, Spectrum Cannabis operates in Australia, South America, Africa and across Europe. Spectrum Cannabis products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded Spectrum to categorize medical cannabis according to THC and CBD levels. Its product lineup includes whole flower cannabis, oils and new innovations such as Softgels. Through product simplification, easy dosing formats, its Compassionate Pricing Program, in addition to ongoing education of healthcare professionals, Spectrum is committed to improving the lives of medical cannabis patients around the globe.
Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include "export from Canada will be replaced with European production", "having sustainable regional production capacity to meet demand is core to the European strategy for Spectrum Cannabis", and "product is fully approved and available following completion of all required control testing within the Czech Republic". Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the successful cultivation of cannabis in Denmark, European medical cannabis regulations and such risks contained in the Company's annual information form dated June 28, 2017 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Canopy Growth Corporation
Copyright 2018 Canada NewsWire
Thanks for sharing. Here is a good statement I got from the thread:
Hi Guys, I think I can give the all-clear on the clearstream issue to the weedstock community. I am german and just talked to my german broker. They said, stock positions which were bought at US/canadian exchanges will NOT be affected in any way because in these cases the deposit is in USA/Canada („Wertpapierrechnung Kanada/USA“).
Only positions acquired via German exchanges will have to be transferred from clearstream to another foreign deposit like CDS. My broker said they would do that automatically in the background, even if the customer doesn´t initiate anything by himself.
Until 28 Sept there is lots of time to do that. No german will have to sell his shares because of the clearstream issue.
Moreover, there is no way, german trading will affect the shar price of any weedstock as weedstock volumes on german exchanges in general are extremely low. For example, Canopy daily average volume is below 40k shares on the volume-strongest german exchange (tradegate).
Canada's cannabis sector may see new deals, capital now that it's legal
https://www.bnn.ca/1.1095951.1529528456
Just got an email from my brokerage PI Financial with an article specific to MJ stock putting WEED at a buy.
Wasn’t that case a year ago when advisor wasn’t totally in favor of me moving some funds into Canopy.